Page 13 - நிறுவனம் ஆஃப் உயிரியல் ப்ராடக்ட்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jun 1, 2021 A Wuhan-based affiliate of China National Pharmaceutical Group (Sinopharm) said the start of operations at a new factory will raise the annual production capacity of its COVID-19 vaccine to at least 1 billion doses. The Wuhan Institute of Biological Products made the announcement in a statement released late on Monday through social media. It did not specify when it will operate the factory at full capacity. Still, the announcement marks a step toward state-backed Sinopharm’s annual capacity target of 3 billion doses for its COVID-19 vaccines. The Beijing Institute of Biological Products, another Sinopharm affiliate whose shot gained emergency-use approval from the World Health Organization, has a factory with annual capacity of 1 billion doses and is also building a new facility.

Cansino biologicsSinovac biotechInstitute of biological productsWorld health organizationChina national pharmaceutical group sinopharmWuhan institute of biological productsChina national pharmaceutical groupWuhan instituteBiological productsBeijing instituteகேன்சினோ உயிரியல்நிறுவனம் ஆஃப் உயிரியல் ப்ராடக்ட்ஸ்உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்சீனா தேசிய மருந்து குழுஉயிரியல் ப்ராடக்ட்ஸ்பெய்ஜிங் நிறுவனம்